[NBIX] Neurocrine Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 39.65 Change: 0.61 (1.56%)
Ext. hours: Change: 0 (0%)

chart NBIX

Refresh chart

Strongest Trends Summary For NBIX

NBIX is in the medium-term down -34% in 2 months. In the long-term up 45% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development stage include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for tourette syndrome schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men?s and women?s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other con

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-11.83% ROE-12.96% ROI
Current Ratio22.19 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities275.28 M Cash From Investing Activities-170.01 M Cash From Operating Activities-4.22 M Gross Profit
Net Profit-23.99 M Operating Profit-25.32 M Total Assets511.2 M Total Current Assets389.42 M
Total Current Liabilities17.55 M Total Debt560 K Total Liabilities44.27 M Total Revenue
Technical Data
High 52 week125.85 Low 52 week68.88 Last close71.98 Last change1%
RSI22.01 Average true range5.04 Beta1.39 Volume828.99 K
Simple moving average 20 days-13.45% Simple moving average 50 days-25.65% Simple moving average 200 days-27.66%
Performance Data
Performance Week-2.51% Performance Month-20% Performance Quart-38.69% Performance Half-32.09%
Performance Year2% Performance Year-to-date-7.23% Volatility daily4.02% Volatility weekly8.98%
Volatility monthly18.41% Volatility yearly63.77% Relative Volume252.57% Average Volume1.13 M
New High New Low

News

2019-01-16 16:01:00 | New INGREZZA® valbenazine Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders

2019-01-16 06:57:11 | 4 Defensive Stocks to Buy Amid Shutdown and Brexit

2019-01-15 16:48:00 | Here’s your guide to the upcoming biotechnology takeover wave

2019-01-15 16:01:00 | Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results

2019-01-14 08:00:00 | Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences

2019-01-11 16:25:40 | Biotech Stocks Are Enjoying Their Best-Ever Start to the Year

2019-01-11 13:32:26 | Is Neurocrine Biosciences, Inc.’s NASDAQ:NBIX CEO Overpaid Relative To Its Peers?

2019-01-10 12:07:29 | 5 Biotech Stocks That Could Face M&A Next!

2019-01-09 08:05:22 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-01-08 08:15:37 | Why Neurocrine Biosciences Stock Rose 9.6% Yesterday

2019-01-07 12:42:05 | Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

2019-01-07 07:15:46 | Neurocrine Biosciences Is a Pharma Stock to Watch

2019-01-07 06:50:00 | Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Loxo Oncology

2019-01-06 18:30:00 | Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones

2019-01-06 10:56:42 | Neurocrine Biosciences Looks Oversold

2019-01-02 16:01:00 | Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-31 07:51:00 | 4 of the Fastest Growing Biotech Stocks in 2019

2018-12-14 08:37:01 | Do Options Traders Know Something About Neurocrine Biosciences NBIX Stock We Don't?

2018-12-13 06:55:00 | Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Synergy Pharmaceuticals

2018-12-12 16:35:00 | Why Under Armour, Neurocrine Biosciences, and XPO Logistics Slumped Today

2018-12-12 12:49:00 | Why Neurocrine Biosciences Is Tanking

2018-12-12 12:19:54 | Why Neurocrine Biosciences Stock Is Plummeting Today

2018-12-12 07:39:00 | Neurocrine Biosciences says trial of Tourette syndrome treatment missed primary goal

2018-12-12 07:30:00 | Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome

2018-12-09 03:31:14 | Should You Buy Neurocrine Biosciences, Inc. NBIX?

2018-12-06 08:03:22 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2018-12-04 08:03:22 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2018-11-27 08:04:43 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2018-11-27 07:15:00 | 3 Top Biotech Stocks to Buy Right Now

2018-11-16 09:04:02 | Neurocrine NBIX Catches Eye: Stock Jumps 6.5%

2018-11-14 17:35:00 | AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress

2018-11-12 15:16:52 | 5 Pharma Stocks to Stay Away From

2018-11-09 08:30:00 | Report: Developing Opportunities within Louisiana-Pacific, Neurocrine Biosciences, Tahoe Resources, Loews, Quotient Technology, and Evolent Health — Future Expectations, Projections Moving into 2018

2018-11-07 16:01:00 | Neurocrine Biosciences to Present at the Jefferies 2018 London Healthcare Conference

2018-11-07 12:17:39 | Does Neurocrine Biosciences Inc’s NASDAQ:NBIX Debt Level Pose A Problem?

2018-11-05 21:25:27 | Edited Transcript of NBIX earnings conference call or presentation 5-Nov-18 9:30pm GMT

2018-11-05 17:15:10 | Neurocrine Biosciences NBIX Q3 Earnings and Revenues Top Estimates

2018-11-05 16:11:15 | Neurocrine: 3Q Earnings Snapshot

2018-11-05 16:01:00 | Neurocrine Biosciences Reports Third Quarter 2018 Financial Results

2018-11-05 07:00:00 | Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Exelixis

2018-11-02 11:41:03 | Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO

2018-10-31 10:25:02 | Neurocrine NBIX to Report Q3 Earnings: What's in the Cards?

2018-10-29 10:31:02 | Neurocrine Biosciences NBIX Q3 Earnings Preview: What to Look Out For

2018-10-25 15:05:02 | How Wall Street Analysts View Alkermes after Q3 Earnings Release

2018-10-25 12:01:41 | Alkermes in the Third Quarter: A Performance Overview

2018-10-23 16:01:00 | Neurocrine Biosciences to Present New Data Analyses on the Long-Term Effects of INGREZZA® valbenazine in Tardive Dyskinesia Patients with Mood Disorders at the 2018 Annual Psych Congress

2018-10-17 09:40:09 | How Acadia Pharmaceuticals Is Positioned Financially

2018-10-17 08:00:00 | Today's Research Reports on Trending Tickers: Lam Research and Applied Materials

2018-10-15 16:01:00 | Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results

2018-10-15 08:35:00 | New Research: Key Drivers of Growth for Neurocrine Biosciences, SS&C Technologies, Quaker Chemical, Sealed Air, KLA-Tencor, and Summit Hotel Properties — Factors of Influence, Major Initiatives and Sustained Production